A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.

The threonine endopeptidase Taspase1 has a critical role in cancer cell proliferation and apoptosis. In this study, we developed and evaluated small molecule inhibitors of Taspase1 as a new candidate class of therapeutic modalities. Genetic deletion of Taspase1 in the mouse produced no overt deficiencies, suggesting the possibility of a wide therapeutic index for use of Taspase1 inhibitors in cancers. We defined the peptidyl motifs recognized by Taspase1 and conducted a cell-based dual-fluorescent proteolytic screen of the National Cancer Institute diversity library to identify Taspase1 inhibitors (TASPIN). On the basis of secondary and tertiary screens the 4-[(4-arsonophenyl)methyl]phenyl] arsonic acid NSC48300 was determined to be the most specific active compound. Structure-activity relationship studies indicated a crucial role for the arsenic acid moiety in mediating Taspase1 inhibition. Additional fluorescence resonance energy transfer-based kinetic analysis characterized NSC48300 as a reversible, noncompetitive inhibitor of Taspase1 (K(i) = 4.22 μmol/L). In the MMTV-neu mouse model of breast cancer and the U251 xenograft model of brain cancer, NSC48300 produced effective tumor growth inhibition. Our results offer an initial preclinical proof-of-concept to develop TASPINs for cancer therapy.

[1]  W. Herr,et al.  O-GlcNAc Transferase Catalyzes Site-Specific Proteolysis of HCF-1 , 2011, Cell.

[2]  Osamu Takeuchi,et al.  BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program , 2010, Science.

[3]  Todd D. Westergard,et al.  Phosphorylation of MLL by ATR is Required for Execution of Mammalian S Phase Checkpoint , 2010, Nature.

[4]  Han Liu,et al.  Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis. , 2010, Cancer research.

[5]  M. Bogyo,et al.  Design, syntheses, and evaluation of Taspase1 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[6]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[7]  D. Braddock,et al.  Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion , 2008, Molecular Cancer Therapeutics.

[8]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[9]  Suely K. N. Marie,et al.  Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR , 2008, Journal of Neuro-Oncology.

[10]  C. Sawyers.  The cancer biomarker problem , 2008, Nature.

[11]  M. Niehof,et al.  EPS15R, TASP1, and PRPF3 are novel disease candidate genes targeted by HNF4alpha splice variants in hepatocellular carcinomas. , 2008, Gastroenterology.

[12]  S. Lindquist,et al.  Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis , 2007, Cell.

[13]  W. Herr,et al.  Species Selectivity of Mixed-Lineage Leukemia/Trithorax and HCF Proteolytic Maturation Pathways , 2007, Molecular and Cellular Biology.

[14]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[15]  Todd D. Westergard,et al.  Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. , 2006, Genes & development.

[16]  S. Korsmeyer,et al.  Uncleaved TFIIA Is a Substrate for Taspase 1 and Active in Transcription , 2006, Molecular and Cellular Biology.

[17]  J. Khan,et al.  Crystal structure of human Taspase1, a crucial protease regulating the function of MLL. , 2005, Structure.

[18]  David Piwnica-Worms,et al.  Real-time imaging of ligand-induced IKK activation in intact cells and in living mice , 2005, Nature Methods.

[19]  G. Salvesen,et al.  Mechanisms of caspase activation. , 2003, Current opinion in cell biology.

[20]  S. Korsmeyer,et al.  Taspase1 A Threonine Aspartase Required for Cleavage of MLL and Proper HOX Gene Expression , 2003, Cell.

[21]  C. Groom,et al.  Proteases as drug targets. , 2003, Biochemical Society symposium.

[22]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[23]  W. Herr,et al.  Proteolytic processing is necessary to separate and ensure proper cell growth and cytokinesis functions of HCF‐1 , 2003, The EMBO journal.

[24]  Paul Tempst,et al.  Proteolytic Cleavage of MLL Generates a Complex of N- and C-Terminal Fragments That Confers Protein Stability and Subnuclear Localization , 2003, Molecular and Cellular Biology.

[25]  M. Cleary,et al.  Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. , 2002, Blood.

[26]  David A. Calhoun,et al.  Drugs targeting the renin–angiotensin–aldosterone system , 2002, Nature Reviews Drug Discovery.

[27]  S. Korsmeyer,et al.  Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. , 2000, Science.

[28]  M. Fortini,et al.  Proteolysis and developmental signal transduction. , 2000, Seminars in cell & developmental biology.

[29]  Joseph L Goldstein,et al.  Regulated Intramembrane Proteolysis A Control Mechanism Conserved from Bacteria to Humans , 2000, Cell.

[30]  Hwai-Chen Guo,et al.  Structural Insights into the Mechanism of Intramolecular Proteolysis , 1999, Cell.

[31]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[32]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[33]  M Aguet,et al.  Inducible gene targeting in mice , 1995, Science.

[34]  B. Furie,et al.  Molecular and cellular biology of blood coagulation. , 1992, The New England journal of medicine.

[35]  R. Kumar,et al.  Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells , 1991, Molecular and cellular biology.

[36]  H. Varmus,et al.  Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice , 1988, Cell.

[37]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[38]  G Svenneby,et al.  [Enzymatic reaction mechanisms]. , 1970, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[39]  S. Elledge,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[40]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[41]  G. Salvesen,et al.  Proteases and the regulation of biological processes , 2003 .

[42]  K Tanaka,et al.  Structure and functions of the 20S and 26S proteasomes. , 1996, Annual review of biochemistry.

[43]  H. Rochefort,et al.  Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. , 1982, Cancer research.